Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

In partnership with Moderna, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) to be used in combination with Keytruda. Merck & Co., Inc. (NYSE:MRK) faces a ...

In the study, mRNA-4157 (V940) – which targets dozens of unique tumour-associated antigens or neoantigens that are expressed by a patient’s cancer cells – was combined with Merck’s PD-1 ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

MSD – known as Merck & Co in the US and Canada – said ... Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks ...

W hen I last covered Moderna stock , I said I was neutral. However, the biotech stock has fallen more than 40% since then, ...

LITESPARK-005 is part of Merck’s development program for Welireg comprised of four phase 3 trials in RCC, in which the company is evaluating Welireg in new combinations with other medicines ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.